Oral contraceptives and the risk of gallbladder disease: a comparative safety study

Etminan, Manyar; Delaney, Joseph A. C.; Bressler, Brian; Brophy, James M.
May 2011
CMAJ: Canadian Medical Association Journal;5/17/2011, Vol. 183 Issue 8, p899
Academic Journal
Background: Recent concerns have been raised about the risk of gallbladder disease associated with the use of drospirenone, a fourth-generation progestin used in oral contraceptives. We conducted a study to determine the magnitude of this risk compared with other formulations of oral contraceptives. Methods: We conducted a retrospective cohort study using the IMS LifeLink Health Plan Claims Database. We included women who were using an oral contraceptive containing ethinyl estradiol combined with a progestin during 1997-2009. To be eligible, women had to have been taking the oral contraceptive continuously for at least six months. We computed adjusted rate ratios (RRs) for gallbladder disease using a Cox proportional hazards model. In the primary analysis, gallbladder disease was defined as cholecystectomy; in a secondary analysis, it was defined as hospital admission secondary to gallbladder disease. Results: We included 2 721 014 women in the cohort, 27 087 of whom underwent surgical or laparoscopic cholecystectomy during the follow-up period. Compared with levonorgestrel, an older second-generation progestin, a small, statistically significant increase in the risk of gallbladder disease was associated with desogestrel (adjusted RR 1.05, 95% confidence interval [CI] 1.01-1.09), drospirenone (adjusted RR 1.20, 95% CI 1.16-1.26) and norethindrone (adjusted RR 1.10, 95% CI 1.06-1.14). No statistically significant increase in risk was associated with the other formulations of oral contraceptive (ethynodiol diacetate, norgestrel and norgestimate). Interpretation: In a large cohort of women using oral contraceptives, we found a small, statistically significant increase in the risk of gallbladder disease associated with desogestrel, drospirenone and norethindrone compared with levonorgestrel. However, the small effect sizes compounded with the possibility of residual biases in this observational study make it unlikely that these differences are clinically significant.


Related Articles

  • Ethinyl Estradiol/Drospirenone (Yasmin): A Newer Oral Contraceptive. Somma, Melissa A. // American Family Physician;5/15/2004, Vol. 69 Issue 10, p2425 

    Presents information on ethinyl estradiol/drospirenone, an oral contraceptive drug. Components; Safety; Incidence of expected side effects; Effectiveness.

  • desogestrel. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p224 

    An encyclopedia entry for the term "desogestrel" is presented. It refers to a progestogen drug used with ethinylestradiol as an ingredient of some combined oral contraceptives. A slightly higher risk of venous thromboembolism is associated with desogestrel compared to other drugs. Some of its...

  • BEYAZ.  // Monthly Prescribing Reference;Nov2010, Vol. 26 Issue 11, pA.7 

    The article offers information on the Beyaz combination oral contraceptive from Bayer HealthCare LLC. It mentions that the said drug contains three-milligram drosperinone, ethinyl estradiol, and levomefolate calcium. Its indications include oral contraception, premenstrual dysphoric disorder...

  • Ethinylestradiol/drospirenone.  // Reactions Weekly;7/19/2008, Issue 1211, p16 

    The article discusses the case of a 30-year-old woman who acquired essential thrombocythemia and splanchnic deep vein thrombosis. The patient, who suffers from Jak2 Val617Phe mutation, developed the diseases while undergoing treatment with oral contraceptive ethinylestradiol/drospirenone. Her...

  • Failure with the new triphasic oral contraceptive Logynon. Fay, R.A. // British Medical Journal (Clinical Research Edition);1/2/1982, Vol. 284 Issue 6308, p17 

    Reports the launching of oral contraceptive Logynon in Great Britain. Composition of Logynon with combinations of ethinyloestradiol and levonorgestrel; Treatment cycles with no pregnancies; Drug failure of oral contraceptives.

  • Ethinylestradiol/norethisterone.  // Reactions Weekly;7/30/2011, Issue 1362, p15 

    The article describes the case of a 68-year-old man with Rendu-Osler disease who developed decreased libido and hypogonadism after receiving ethinylestradiol/norethisterone for the treatment of severe anaemia.

  • Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension. Kozma, Chris M.; Dirani, Riad G.; Canuso, Carla M.; Mao, Lian // Annals of General Psychiatry;2010, Vol. 9, p24 

    Background: The purpose of this analysis was to evaluate relationships between hospital admission or discharge and scores for symptom or functioning in patients with schizophrenia. Methods: Data were from three 52-week open-label extensions of the double-blind pivotal trials of paliperidone...

  • Ethinylestradiol/levonorgestrel.  // Reactions Weekly;7/20/2013, Issue 1462, p21 

    The article presents a case study about the development of peripheral arterial disease in a 40-year-old woman after receiving ethinyl estradio/loevonorgestrel.

  • Ethinylestradiol/etonogestrel.  // Reactions Weekly;10/29/2016, Vol. 1625 Issue 1, p98 

    The article presents a case study of a 18-year-old-woman admitted due five days of worsening intermittent periumbilical, epigastric and right upper quadrant (RUQ) abdominal pain, who developed acute mesenteric venous thrombosis (MVT) while using ethinylestradiol/etonogestrel vaginal ring.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics